Previous 10 | Next 10 |
Soligenix (NASDAQ:SNGX) +26% FDA Grants soligenix orphan drug designation for the treatment of T-cell lymphoma Eloxx Pharmaceuticals (NASDAQ:ELOX) +22% announces fast track designation for ELX-02 for the treatment of cystic fibrosis patients with nonsense mutations Cardiff Oncology ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re starting off the day with a dive into the biggest pre-market stock movers for Thursday. Source: ventdusud / Shutterstock.com There’s a lot of reason for stocks to be moving ...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that ProQR management will host...
Companies will collaborate to develop editing oligonucleotides directed to up to five targets u sing ProQR’s proprietary Axiomer ® RNA editing platform ProQR to receive $ 5 0 million ...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 06, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced a virtual oral presentation of data...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Comp...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Compa...
Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290 -mediated LCA10 on track for H1 2022 QR-421a pivotal Sirius and Celeste Phase 2/3 trials in Usher syndrome and retinitis pigmentosa expected to start by year end 2021 Initial clinical da...
PRQR is using antisense RNA technology to target inherited retinal diseases. They have strong data from one indication, and decent data from another. PRQR looks interesting ahead of next year's pivotal data. For further details see: ProQR Therapeutics: Looks Interesting ...
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Compa...
News, Short Squeeze, Breakout and More Instantly...
ProQR Therapeutics N.V. Company Name:
PRQR Stock Symbol:
NASDAQ Market:
ProQR Therapeutics N.V. Website:
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massa...
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27 th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight data Martin Maier, PhD nominated to Board with Annual General Meeting scheduled f...
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides Preclinical proof of concept for the Company’s AX-0810 pr...